From: Syk inhibitors in clinical development for hematological malignancies
Phase | Diseases | Interventions | NCT ID |
---|---|---|---|
2 | CLL, MCL, DLBCL, non-FL iNHL, FL | Entospletinib monotherapy | NCT01799889 |
1/2 | AML | Entospletinib monotherapy | NCT02343939 |
2 | CLL, MCL, DLBCL, iNHL | Entospletinib with idelalisib | NCT01796470 |
1 | ALL | Entospletinib, vincristine, dexamethasone | NCT02404220 |
2 | GVHD | Entospletinib, placebo, corticosteroids | NCT02701634 |
1 | Â | Entospletinib | NCT02521376 |
1 | B-cell malignancies | Entospletinib, idelalisib, ONO/GS-4059 | NCT02457598 |
1, 2 | NHL | Entospletinib, vincristine | NCT02568683 |